Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hartz

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
Journal of Medicinal Chemistry|August 5, 2024
Atropisomerism Observed in Galactose-Based Monosaccharide Inhibitors of Galectin-3 Comprising 2-Methyl-4-phenyl-2,4-dihydro-3<i>H</i>-1,2,4-triazole-3-thioneDavid S Yoon, Chunjian Liu, Prasada Rao Jalagam, et al.
The Journal of Rheumatology|August 17, 2013
A randomized controlled trial of an internal family systems-based psychotherapeutic intervention on outcomes in rheumatoid arthritis: a proof-of-concept studyNancy A Shadick, Nancy F Sowell, Michelle L Frits, et al.
Journal of Medicinal Chemistry|May 26, 2023
Discovery of 2-(Anilino)pyrimidine-4-carboxamides as Highly Potent, Selective, and Orally Active Glycogen Synthase Kinase-3 (GSK-3) InhibitorsRichard A Hartz, Vijay T Ahuja, Guanglin Luo, et al.
ACS Medicinal Chemistry Letters|November 20, 2024
Invention of VH-937, a Potent HIV-1 Maturation Inhibitor with the Potential for Infrequent Oral Dosing in HumansSing-Yuen Sit, Yan Chen, Jie Chen, et al.
Journal of Medicinal Chemistry|July 16, 2021
Discovery, Structure-Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic PainRichard A Hartz, Vijay T Ahuja, Susheel J Nara, et al.
Journal of Medicinal Chemistry|June 26, 2009
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonistsRichard A Hartz, Vijay T Ahuja, Maria Rafalski, et al.
Journal of Medicinal Chemistry|December 4, 2009
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonistRichard A Hartz, Vijay T Ahuja, Xiaoliang Zhuo, et al.
Bioorganic & Medicinal Chemistry Letters|February 19, 2015
Design, synthesis, and evaluation of phenylglycinols and phenyl amines as agonists of GPR88Carolyn D Dzierba, Yingzhi Bi, Bireshwar Dasgupta, et al.
Bioorganic & Medicinal Chemistry Letters|September 27, 2012
[18F](R)-5-chloro-1-(1-cyclopropyl-2-methoxyethyl)-3-(4-(2-fluoroethoxy)-2,5-dimethyl phenylamino)pyrazin-2(1H)-one: introduction of N3-phenylpyrazinones as potential CRF-R1 PET imaging agentsJeffrey A Deskus, Douglas D Dischino, Ronald J Mattson, et al.
Journal of Medicinal Chemistry|February 16, 2022
Bicyclic Heterocyclic Replacement of an Aryl Amide Leading to Potent and Kinase-Selective Adaptor Protein 2-Associated Kinase 1 InhibitorsRichard A Hartz, Vijay T Ahuja, Susheel J Nara, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Journal of Medicinal Chemistry|August 5, 2024
Atropisomerism Observed in Galactose-Based Monosaccharide Inhibitors of Galectin-3 Comprising 2-Methyl-4-phenyl-2,4-dihydro-3<i>H</i>-1,2,4-triazole-3-thioneDavid S Yoon, Chunjian Liu, Prasada Rao Jalagam, et al.
The Journal of Rheumatology|August 17, 2013
A randomized controlled trial of an internal family systems-based psychotherapeutic intervention on outcomes in rheumatoid arthritis: a proof-of-concept studyNancy A Shadick, Nancy F Sowell, Michelle L Frits, et al.
Journal of Medicinal Chemistry|May 26, 2023
Discovery of 2-(Anilino)pyrimidine-4-carboxamides as Highly Potent, Selective, and Orally Active Glycogen Synthase Kinase-3 (GSK-3) InhibitorsRichard A Hartz, Vijay T Ahuja, Guanglin Luo, et al.
ACS Medicinal Chemistry Letters|November 20, 2024
Invention of VH-937, a Potent HIV-1 Maturation Inhibitor with the Potential for Infrequent Oral Dosing in HumansSing-Yuen Sit, Yan Chen, Jie Chen, et al.
Journal of Medicinal Chemistry|July 16, 2021
Discovery, Structure-Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic PainRichard A Hartz, Vijay T Ahuja, Susheel J Nara, et al.
Journal of Medicinal Chemistry|June 26, 2009
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonistsRichard A Hartz, Vijay T Ahuja, Maria Rafalski, et al.
Journal of Medicinal Chemistry|December 4, 2009
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonistRichard A Hartz, Vijay T Ahuja, Xiaoliang Zhuo, et al.
Bioorganic & Medicinal Chemistry Letters|February 19, 2015
Design, synthesis, and evaluation of phenylglycinols and phenyl amines as agonists of GPR88Carolyn D Dzierba, Yingzhi Bi, Bireshwar Dasgupta, et al.
Bioorganic & Medicinal Chemistry Letters|September 27, 2012
[18F](R)-5-chloro-1-(1-cyclopropyl-2-methoxyethyl)-3-(4-(2-fluoroethoxy)-2,5-dimethyl phenylamino)pyrazin-2(1H)-one: introduction of N3-phenylpyrazinones as potential CRF-R1 PET imaging agentsJeffrey A Deskus, Douglas D Dischino, Ronald J Mattson, et al.
Journal of Medicinal Chemistry|February 16, 2022
Bicyclic Heterocyclic Replacement of an Aryl Amide Leading to Potent and Kinase-Selective Adaptor Protein 2-Associated Kinase 1 InhibitorsRichard A Hartz, Vijay T Ahuja, Susheel J Nara, et al.
Pageof 11